1Mart KA,CHppa F,Leisenring W,el a1.Viraconazole versus fuconazole for prevention of fungal infections in allogeneic stem cell transplant patients[J].Blood,2003,2:2.
3Walsh TJ,Anaissie EJ,Denning DW,et al.Treatment of aspergillosis:clinical practice guidelines of the Infectious Diseases Society of America[J].Clin Infect Dis,2008,46:327-360.
6Ikeda F.Antifungal activity and clinical efficacy of micafungin (funguard)[J].Jpn J Med Mycol,2005,46:217.
7Tawara S,Ikeda F,Maki K,et al.In vitro activities of a new lipopeptide antifungal agent micafungin against a variety of clinically important fungi[J].Antimicrob Agents Chemother,2000,44(1):57.
8Chandrasekar P H,Sobel J D.Micafungin:a new echiocandin[J].Clin Infect Dis,2006,42(8):1171.
9Mary F H,Pharm D,Helen E S,et al.Pharmacokinetics of Micafuungin in healthy volunteers,volunteers with modertate liver disease,and volunteers with renal dysfunction[J].J Clin Pharmacol,2005,45:1145.
10Dewet N,Llanoscuentas A,Suleiman J,et al.A randomized,double-blind,parallel group,dose response study of micafungin compared with fluconazole for the treatment of esophageal Candidiasis in HIV-positive patients[J].Clin Infect D is,2004,39(6):842.
